Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 6, 2022; 10(10): 3101-3112
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3101
Table 2 Patient’s status at the time of study enrollment
| Treatment status | |
| Still going on | 35.7% |
| Stopped due to neuropathy | 30.8% |
| Stopped due to toxicity | 16.7% |
| Finished chemotherapy | 16.8% |
| Types of toxicity | |
| Neuropathy | 30.8% |
| Hematologic | 28.2% |
| Digestive | 12.4% |
| Dermatologic | 3.5% |
| Mixed | 25.1% |
- Citation: Prutianu I, Alexa-Stratulat T, Cristea EO, Nicolau A, Moisuc DC, Covrig AA, Ivanov K, Croitoru AE, Miron MI, Dinu MI, Ivanov AV, Marinca MV, Radu I, Gafton B. Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study. World J Clin Cases 2022; 10(10): 3101-3112
- URL: https://www.wjgnet.com/2307-8960/full/v10/i10/3101.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i10.3101